Business and Finance

Annual EY Firepower report finds a 'feverish' environment for M&A

January 19, 2016

Deal value soared above $300 billion in 2015, but will the dealmaking sustain Big Pharma companies?

New life sciences capital-construction projects totaled $15 billion in 2015

January 12, 2016

Construction index shows a steady level of North American activity

New year, new names for BIO and Canada's pharma trade association, and more

January 06, 2016

'Innovation' is the recurring theme

Full-line distributor sales reached $350 billion in 2013, representing 91% of pharma sales

January 05, 2016

HDMA's 2015-16 Factbook updates member financial, operational performance

Biosimilars: why deep discounts may become the dominant paradigm

November 05, 2015

European experience to date indicates a changing perspective on biosimilar pricing

A Conversation with George Barrett, Cardinal Health

November 05, 2015

Resources for managing global drug pricing decisions are limited, says survey

October 20, 2015

Model N/Highpoint survey points to better integration of pricing and contract data

Daiichi Sankyo US shifts to specialty-pharma focus; cuts US staff by nearly 50%

October 20, 2015

Company has 18 products in its US pipeline

A Conversation with Steve Collis, AmerisourceBergen

August 31, 2015

A Conversation with Gary McWalters, TGaS Advisors

June 30, 2015